[Update 20/07/2015] After successfully closing its Underwritten Public Offering, DBV finally raised €255M ($281,5M) on the NASDAQ.
Original article from 16/07/2015:
DBV Technologies is going for its second fundraising on the NASDAQ, hoping for €223M. €68.6M were already secured last week from Baker Bros. Advisors LP. The money will allow the company to stay independent all the way until they deliver a potential new blockbuster.
Food allergies are on the march, especially in industrialized countries. According to the American Centers for Disease Control and Prevention, the rate of affected children increased by 50% between 1997 and 2011. There is neither an explanation for this increase nor a cure for the allergies.
Therefore, food allergies represent a huge market for pharma companies. DBV technologies are one of the pioneers in this field, using its special patch system to treat peanut, milk and egg allergies. DBV’s lead candidate Viaskin, a peanut allergy treatment received breakthrough therapy designation from the FDA and – should everything work out –